Powered by lexis nexis

FACIT Announces Investment in Propellon Therapeutics

Mar 22, 2017 - PR Newswire

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development

FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. FACIT's investment, combined with non-dilutive capital, achieves a targeted $3.0M financing for the lead program. The seed funding enables Propellon to accelerate the nomination of a candidate d...